ARCHIVES

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

This article is from The Cancer Letter archive.

Vol. 11 No. 14 | April 5, 1985

Download PDF Visit The Full Archive

Related Articles

FDA News: FDA Taking Comments on “First Generic” ANDA Process

November 21, 2014

NCI Community Cancer Centers RFP Issued; Advisors Criticize Project Structure.

November 10, 2006

Rising Costs at NCI Threaten To Overtake Slim Increases In Budget Appropriations

March 28, 2014

Segmental Study Finally Published, Says Less Surgery as Good as More, Radiation Helped

March 22, 1985

BMT Ok For some Stage IV Breast Cancer, Blues Advisor Say

March 8, 1996

FDA Deputy Commissioner Gottlieb To Return To AEI.

December 15, 2006